OpenLobby.EU
Explore

Huvepharma

Research, development, registration, marketing and distribution of veterinary medicines, veterinary vaccines, feed additives, biocides and pharmaceutical active substances.

Lobbying Activity

Meeting with Ekaterina Zaharieva (Commissioner) and

27 Feb 2025 · Opportunities for cooperation between the EU and India in the fields of research, innovation, Start Ups and innovation ecosystems.

Meeting with Carmen Avram (Member of the European Parliament)

9 Dec 2022 · Pharmaceutical and Feed Additives

Response to Improving access to and availability, sharing and re-use of chemical data for the purpose of chemical safety assessments

16 Aug 2022

We welcome initiatives that aim to harmonise rules, but notes these often raise the overall cost and impact by harmonising to the highest common denominator. The key points we would like to emphasise in this consultation are: 1. The need to support investment in R&D and innovation in the EU, to avoid disincentives to investment through by allowing lower market entry costs to commercial competitors free-riders. The EFSA Transparency Regulation is not a model to follow because the application data file is disclosed to the wider public prior to product approval, deterring companies from launching products in the EU first. 2. The need to support investment in R&D and innovation in the EU by not undermining trade secret protection law, intellectual property rights and regulatory data protection and recognise the important monetary value of both new data and legacy data. 3. The transparency of data is important, but it is critical that the information contain appropriate context to avoid misinterpretation and misuse of data, and that confidential data is not made public which could negatively impact innovation. 4. The need to rigorously pursue the EC objectives through better regulation initiatives to reduce the administrative burden on EU business and agencies. The EFSA Transparency Regulation has led to a dramatic increase of the administrative burden by the applicant and should not be used as a model. . 5. The need to respect better regulation principles through impact assessments; this initiative potentially will have significant impacts on business in the EU, and the statements to the contrary in the ‘Call for evidence’ need to be fully substantiated with evidence. Consequently, we urge the Commission to invest more time to evaluate the impact and long term consequences of this horizontal legislative initiative on access to data together with stakeholders.
Read full response